A phase Ib/II clinical trial of AMY-101 in patients with the rare diseases C3G (C3 glomerulopathy).
Phase of Trial: Phase I/II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs AMY 101 (Primary)
- Indications Membranous glomerulonephritis
- Focus Adverse reactions; Therapeutic Use
- 18 Dec 2017 New trial record
- 13 Dec 2017 According to a Amyndas Pharmaceuticals media release, company is now planning to initiate Phase Ib/II clinical trials in patients with the rare diseases C3G and PNH for which AMY-101 has received orphan designation from the FDA and the EMA.